Novartis Gains Approval for First Malaria Drug for Newborns and Infants
Novartis has received Swissmedic approval for Coartem Baby, the first malaria treatment specifically for newborns and young infants, aiming to fill a treatment gap and increase access in malaria-endemic regions, especially in Africa, on a largely not-for-profit basis.